Rapid Communication
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Nov 7, 2008; 14(41): 6401-6407
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
Zhao-Hui Huang, Dong Hua, Xiang Du, Li-Hua Li, Yong Mao, Zhi-Hui Liu, Ming-Xu Song, Xi-Ke Zhou
Zhao-Hui Huang, Dong Hua, Li-Hua Li, Yong Mao, Zhi-Hui Liu, Ming-Xu Song, Xi-Ke Zhou, Wuxi Oncology Institute, the Fourth Affiliated Hospital of Suzhou University, Wuxi 214062, Jiangsu Province, China
Zhao-Hui Huang, Xiang Du, Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China
Author contributions: Huang ZH and Hua D was responsible for the study design, data extraction and statistics and Du X for the academic instructions; and Li LH, Mao Y, Liu ZH, Song MX and Zhou XK performed the research.
Supported by A Grant From Scientific and Technologic Bureau of Wuxi, CLZ00612
Correspondence to: Dong Hua, Wuxi Oncology Institute, the Fourth Affiliated Hospital of Suzhou University, 200 Huihe Road, Wuxi, 214062, Jiangsu Province, China. hud21cn@medmail.com.cn
Telephone: +86-510-88683506 Fax: +86-510-88683507
Received: July 6, 2008
Revised: September 19, 2008
Accepted: September 26, 2008
Published online: November 7, 2008
Abstract

AIM: To determine the influence of excision repair cross complementing group 1 (ERCC1) codon 118 polymorphism and mRNA level on the clinical outcome of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

METHODS: Eighty-nine gastric cancer patients treated with oxalipatin-based adjuvant chemotherapy were included in this study. ERCC1 codon 118 C/T polymorphism was tested by polymerase chain reaction-ligation detection reaction (PCR-LDR) method in peripheral blood lymphocytes of those patients; and the intratumoral ERCC1 mRNA expression was measured using reverse transcription PCR in 62 patients whose tumor tissue specimens were available.

RESULTS: No significant relationship was found between ERCC1 codon 118 polymorphism and ERCC1 mRNA level. The median relapse-free and overall survival period was 20.1 mo and 28.4 mo, respectively. The relapse-free and overall survivals in patients with low levels of ERCC1 mRNA were significantly longer than those in patients with high levels (P < 0.05), while there was no significant association found between ERCC1 118 genotypes and the disease prognosis. Multivariate analysis also showed that ERCC1 mRNA level was a potential predictor for relapse and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy (P < 0.05).

CONCLUSION: ERCC1 codon 118 polymorphism has no significant impact on ERCC1 mRNA expression, and the intratumoral ERCC1 mRNA level but not codon 118 polymorphism may be a useful predictive parameter for the relapse and survival of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

Keywords: Gastric cancer; Adjuvant chemotherapy; Excision repair cross complementing group 1; Gene polymorphism